▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #1216 by analyst upside · 2026-09-27
CYTK
Cytokinetics, Incorporated
Healthcare · Market Cap $9B · P/E 0x
ANALYST PRICE TARGET
+70.0%
implied upside to consensus target
Current Price $64.66
Consensus Target $109.9
Bull Target $146.0
Bear Target $85.0
Analysts Covering 20
ANALYST CONSENSUS - BUY
Strong Buy
6
Buy
12
Hold
2
Sell
0
52-Week Low $50.15
52-Week High $88.31
YTD Return +4.7%
FUNDAMENTALS
Market Cap $9B
P/E Ratio (TTM) N/A
Forward P/E N/A
EPS (TTM) $-7.22
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $68M
Profit Margin N/A
52-WEEK RANGE
52-Week Low $50.15
52-Week High $88.31
Current Price $64.66
Bear Target $85.0
Bull Target $146.0
● Now $64.66 ● Target $109.9
TRADING DATA
Avg Volume 1.9M
YTD Return +4.7%
Analyst Count 20
Consensus Buy
Upside to Target +70.0%
Last Updated 2026-09-27

ANALYST SUMMARY

Cytokinetics, Incorporated (CYTK) is currently trading at $64.66 with a Wall Street consensus price target of $109.9, implying potential upside of 70.0% over the next 12 months. 20 analysts currently cover CYTK, with a consensus rating of Buy - 90% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $146.0, while the most cautious has a target of $85.0.

CYTK operates in the Healthcare sector with a market capitalisation of $9B. The stock is up 4.7% year-to-date and is currently trading near the lower end of its 52-week range of $50.15 – $88.31.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

GMED +38.5%
Globus Medical, Inc.
$10B · P/E 19.1x · Buy
UHS +8.7%
Universal Health Services, Inc.
$11B · P/E 7.3x · Hold
HNGE +13.1%
Hinge Health, Inc.
$8B · P/E 11.6x · Buy
ATR +37.4%
AptarGroup, Inc.
$8B · P/E 22.6x · Buy
DVA +23.2%
DaVita Inc.
$11B · P/E 15.1x · Hold

RECENT ANALYST CALLS

Upgrade/downgrade history for CYTK, with each firm's 90-day track record across all stocks we track. See full firm rankings →

HC Wainwright & Co. reit
Buy → Buy 2026-08-31 31% win rate (48 calls)
Barclays - Reiterated
Overweight → Overweight 2026-08-13 Building track record
JP Morgan - Reiterated
Overweight → Overweight 2026-08-13 43% win rate (7 calls)
Truist Securities - Reiterated
Buy → Buy 2026-08-10 Building track record
RBC Capital - Reiterated
Outperform → Outperform 2026-08-07 Building track record
Citizens - Reiterated
Market Outperform → Market Outperform 2026-08-07 Building track record
Needham - Reiterated
Buy → Buy 2026-08-07 20% win rate (5 calls)
RBC Capital - Reiterated
Outperform → Outperform 2026-07-07 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
56
out of 100
Coverage depth
23/30
Consensus clarity
11/30
Vote unanimity
20/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →